Market Overview

UPDATE: Goldman Sachs Raises PT on Accretive Health to $21 (AH)


Goldman Sachs is out with its report today on Accretive Health (NYSE: AH), raising its PT from $14 to $21.

In a note to clients, Goldman Sachs states, "We increase our 12 month price target to $21 from $14, which is based on a blend of our EV/EBITDA (50%), PEG (30%), and DCF (20%) valuation analyses. Our price target rises given we roll forward to 2012E estimates (from 2011E) and assume greater long-term EBITDA margin expansion."

Goldman Sachs maintains Neutral on AH.

Shares of AH closed Wednesday at $20.00.


Related Articles (AH)

View Comments and Join the Discussion!

Posted-In: accretive health Goldman SachsAnalyst Color Price Target Analyst Ratings

Latest Ratings

PLNTRaymond JamesDowngrades
EVRGEvercore ISI GroupUpgrades69.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at